• Aspire Biopharma closed a private placement of 13,750 shares of Series A Convertible Preferred Stock on April 15.
• Gross proceeds totaled USD 11 million, including conversion of USD 943,801 of existing debt into preferred shares.
• Terms allow conversion into common stock at 80% of lowest closing price over five trading days before conversion, subject to a floor price.
• Conversion is capped at 4.99% beneficial ownership, adjustable up to 9.99% with a 61-day notice period.
• RBW Capital Partners received a placement agent fee of USD 900,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-017115), on April 16, 2026, and is solely responsible for the information contained therein.